You are currently logged into
POZ Directory - My Account or Log Out
POZ POZ
  • Home
  • Basics
    • Basics
    • Introduction
    • HIV Transmission and Risks
    • HIV Testing
    • HIV Prevention
    • Newly Diagnosed
    • Starting HIV Treatment
    • HIV Medications
    • HIV Drug Assistance Programs
    • HIV and Liver Disease
    • VIH/SIDA en Español
  • News
    • News
    • Newsfeed
    • Science News
    • Features
    • Opinions
    • Conferences
    • Slideshows
    • Videos
    • POZ at Home
    • POZ TV
    • POZ Stories
    • POZ 100
    • By Author
    • RSS Links
  • Hot Topics
    • Hot Topics
    • POZ Awards
    • POZ at 25
    • POZ 100
    • Advocacy
    • COVID-19
    • Criminalization
    • Cure
    • Long-Term Survivors
    • Newly Diagnosed
    • PrEP
    • Prevention
    • Undetectable (U=U)
    • Youth
  • Magazine
    • Magazine
    • Current Issue
    • Archives
    • Digital Editions
    • POZ Focus
    • POZ en Español
    • Subscriptions
    • Email Newsletters
  • Blogs
    • Blogs
    • Recent Posts
    • Browse Bloggers
    • RSS Links
  • Community
    • Community
    • POZ Personals
    • POZ Stories
    • POZ 100
    • Community
    • AIDS Is Everyday
    • Forums
    • Polls
    • Surveys
    • Quizzes
    • Ask POZ
    • Services Directory
    • Calendar
    • Jobs
    • Bookstore
  • About Us
    • About Us
    • About Us
    • Masthead
    • Awards
    • Press Releases
    • Advertise
    • Contact Us
  • Facebook
  • Twitter

© 2021 Smart + Strong. All Rights Reserved. Terms of use and Your privacy. Smart + Strong® is a registered trademark of CDM Publishing, LLC.

© 2021 Smart + Strong.
All Rights Reserved.
Terms of use and
Your privacy.
Smart + Strong®
is a registered trademark of CDM Publishing, LLC.

Advertisement

Share


Twitter
Facebook
Pinterest
Tumblr
Email

#IDWeek 2018

Tweet
  • Share

The U.N. General Assembly Hall during the High-level Meeting on HIV/AIDS.

Conferences

Merck Files With FDA for Expanded Approval of Pifeltro and Delstrigo

An OK would add an indication for the use of these HIV medications among those switching from stable regimens.

Tivicay

Tivicay Plus Boosted Prezista Shows Promise as Two-Drug HIV Regimen

However, the regimen appears much less potent for those who aren’t virally suppressed.

Switching to Janssen’s Symtuza Is Safe and Effective Up to 96 Weeks

Researchers compared switching to Symtuza with staying on an effective regimen of a boosted protease inhibitor plus Truvada.

Researchers Report Rare PrEP Failure in San Francisco

Experts emphasize that Truvada for HIV prevention remains highly effective.

Switching to Merck’s New HIV Regimen Delstrigo Is Safe and Effective

According to 48-week data from a recent study, Delstrigo posted good marks against other HIV treatments.

Advertisement

Stay Logged In?

You have been inactive for 60 minutes and will be logged out in . Any updates not saved will be lost.

You Have Been Logged Out

Click here to log back in.